Author:
Cardoso F.,Costa A.,Senkus E.,Aapro M.,André F.,Barrios C.H.,Bergh J.,Bhattacharyya G.,Biganzoli L.,Cardoso M.J.,Carey L.,Corneliussen-James D.,Curigliano G.,Dieras V.,El Saghir N.,Eniu A.,Fallowfield L.,Fenech D.,Francis P.,Gelmon K.,Gennari A.,Harbeck N.,Hudis C.,Kaufman B.,Krop I.,Mayer M.,Meijer H.,Mertz S.,Ohno S.,Pagani O.,Papadopoulos E.,Peccatori F.,Penault-Llorca F.,Piccart M.J.,Pierga J.Y.,Rugo H.,Shockney L.,Sledge G.,Swain S.,Thomssen C.,Tutt A.,Vorobiof D.,Xu B.,Norton L.,Winer E.
Reference65 articles.
1. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2);Cardoso;Simultaneous publication in The Breast,2014
2. Global Status of Advanced/Metastatic Breast Cancer 2005–2015 Decade Report. www.breastcancervision.com and www.abc-lisbon.org (27 October 2016, date last accessed).
3. SEER Cancer Statistics Review, 1975–2013;Howlader,2016
4. Trends in survival in metastatic breast;Sundquist;Cancer Eur J Cancer,2010
5. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer;Kobayashi;Surg Today,2016